辛伐他汀对初发2型糖尿病患者颈动脉内膜中层厚度与血管内皮舒张功能的临床研究

目的研究使用辛伐他汀对初发2型糖尿病(T2DM)患者颈动脉内膜中层及血管内皮舒张功能的影响。方法 120例初发T2DM患者在应用正规胰岛素降糖治疗基础上,随机分为辛伐他汀治疗组70例,对照组50例。治疗4个月测量颈动脉内膜中层厚度和测定血管内皮舒张功能。结果与治疗前比较,治疗组颈动脉内膜中层厚度变薄,肱动脉内皮依赖性舒张功能及非内皮依赖性舒张功能有显著性改善(均P<0.05)。结论早期应用辛伐他汀可减少初发T2DM患者颈动脉内膜中层厚度,对其血管内皮舒张功能亦有明显改善。

Quality control of ultrasonic measurement of carotid artery intima-media thickness

Background To report quality control methods and baseline reproducibility data of the ultrasound measurements of carotid artery intima-media thickness in the project of Establishment of an Integrated System for Coronary Heart Disease Prevention and Treatment. Methods Standard ultrasound scanning and measuring protocols were established by the study group. All sonographers and readers were trained by the carotid ultrasound core lab and all digital ultrasound images were centrally read. Ten subjects were scanned twice （with 1 week interval） by 2 sonographers independently and images were read by a single reader to evaluate the sonographer variability. Twenty subjects＇ images were read twice （with 1 week interval） by a single reader to assess the reader variability and the reproducibility of IMT measured at different carotid segments. Results The intraclass correlation （ICC） of intra- and inter-sonographer and intra- reader for mean IMT measurements was 0.99, 0.98 and 0.97 respectively; while for max IMT, it was 0.97, 0.99 and 0.95 respectively. Among different carotid segments and sites, ICC for mean 1MT measurements of common carotid （CCA）, carotid artery bulb （Bulb）, internal carotid artery （ICA）, overall near wall and overall far wall was 0.97, 0.99, 0.89, 0.93 and 0.98 respectively. Conclusion The reproducibility of IMT measurements according to our protocol is acceptable, although better reproducibility is found when measuring the mean IMT than max IMT, CCA and Bulb IMT than ICA IMT, and far wall IMT than near wall IMT.

普罗布考、瑞舒伐他汀对脑梗死伴糖尿病S100蛋白的影响

选择2017年3月~2018年9月脑梗死合并糖尿病患者96例,随机平分为对照组在此基础上加用瑞舒伐他汀,观察组在对照组基础上加用普罗布考,用药1年。结果治疗后,两组P25、CAIMT、内膜斑块面积、易损斑块水平均降低,且观察组(1.03±0.28)mm、(0.47±0.15)cm2、37.50%水平低于对照组(1.24±0.33)mm、(0.60±0.22)cm2、58.33%,(P<0.05);两组S100蛋白均降低,且观察组(0.12±0.03)μg/L低于对照组(0.24±0.04)μg/L,(P<0.05)。结论对脑梗死伴糖尿病患者采用普罗布考联合瑞舒伐他汀治疗有助于改善颈动脉粥样硬化,改善脑部氧代谢功能。

Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus

In the present study,we aimed to investigate the effects of linagliptin on inflammatory factors and carotid intima-media thickness(CIMT)in newly diagnosed type 2 diabetes mellitus(T2 DM)patients with carotid atherosclerotic disease(CAD).A total of 326 patients with newly diagnosed T2 DM complicated with CAD were randomly divided into two groups.There were 163 patients in the control group,who were treated with metformin monotherapy.There were 163 patients in the experimental group,who were treated with metformin in combination with linagliptin.The CIMT before and after treatment was measured by color Doppler ultrasound,and the contents of IL-6 and IL-1βbefore and after treatment were detected by ELISA.The levels of inflammatory factors and CIMT before and after treatment were compared between the two groups,and the correlation between IL-6,IL-1βand CIMT was studied.After 24 weeks of treatment,the levels of inflammatory factors and CIMT in the experimental group were significantly lower compared with the control group(P<0.01),and the serum levels of IL-6 and IL-1βwere positively correlated with CIMT.In the present study,we concluded that linagliptin could improve the levels of inflammatory factors and CIMT in newly diagnosed T2 DM patients with CAD,and IL-6 and IL-1βmight participate in the occurrence and development of CAD by influencing CIMT.